A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors

NCT05457517 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: YL-13027，Sintilimab

Sponsor

Shanghai YingLi Pharmaceutical Co. Ltd.